Inactive Instrument

Kyung Nam Pharm Co Ltd Share Price Korea S.E.

Equities

Pharmaceuticals

End-of-day quote Korea S.E.
- - Intraday chart for Kyung Nam Pharm Co Ltd
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 5.9TCr 4.37Cr 0 363.4Cr Sales 2023 6.84TCr 5.06Cr 0 421.57Cr Capitalization 5.99TCr 4.43Cr 0 368.74Cr
Net income 2022 -677.9Cr -50.16L - -42Cr Net income 2023 -2.1TCr -1.55Cr - -129.32Cr EV / Sales 2022 1.19 x
Net cash position 2022 1.23TCr 90.91L 0 76Cr Net Debt 2023 1.63TCr 1.21Cr 0 100.5Cr EV / Sales 2023 1.11 x
P/E ratio 2022
-11.5 x
P/E ratio 2023
-2.84 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 72.08%
More Fundamentals * Assessed data
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding CI
Kyung Nam Pharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kyung Nam Pharm Co.,Ltd. agreed to acquire 9.94% stake in ILYA Co., Ltd from Kang, Jae Woo and Han, Seung Ja for KRW 7 billion. CI
Enterpartners Co., LTD announced that it expects to receive KRW 26.599899939 billion in funding from Kyung Nam Pharm Co.,Ltd. CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 9.02379645 billion in funding from Blueberry NFT CO.,LTD. CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 8 billion in funding from Metaplex Co., Ltd., and other investors CI
Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 8 billion in funding from Metaplex Co., Ltd., and other investors CI
Kyung Nam Pharm HealthCare Co.,Ltd. announced that it has received KRW 3.999997925 billion in funding from Blueberry NFT CO.,LTD., Kyung Nam Pharm Co.,Ltd. CI
Kyung Nam Pharm HealthCare Co.,Ltd. announced that it expects to receive KRW 3.999997925 billion in funding from Blueberry NFT CO.,LTD., Kyung Nam Pharm Co.,Ltd. CI
Kyung Nam Pharm Co.,Ltd., Virtualtek Corp and Ventage Partners Co., Ltd. agreed to acquire 9.32% stake in Livefinancial Co.,Ltd. for KRW 5.8 billion. CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 1.9999997 billion in funding from KyungNam Biopharma CO.,LTD. CI
Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 14.5 billion in funding from Kartoon Korea CO.,LTD. and other investors CI
More news
Managers TitleAgeSince
Chief Executive Officer 46 -
Comptroller/Controller/Auditor 77 -
Members of the board TitleAgeSince
Director/Board Member 46 -
Chief Executive Officer 46 -
Director/Board Member 53 -
More insiders
KYUNG NAM PHARM.CO., LTD. is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The Company provides vitamin products under the brand name LEMONA. It supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW